Drug Watch
This detailed and up-to-date list is made possible by the hard work and research performed by the Hepatitis B Foundation. Please help us continue to offer this kind of essential resource for the treatment of hepatitis B with a donation toward our important programs. Donate here.
To learn more about the drug development process, click here.
Compounds in Development for Chronic Hepatitis B
Updated June 10, 2026
FAMILY / DRUG NAME |
MECHANISM |
COMPANY |
WEBSITE |
|
|||||
| Interferons: Mimic infection-fighting immune substances naturally produced in the body | |||||||||
| Intron A (Interferon alfa 2b) | Immunomodulator | Merck, USA | merck.com | Approved 1991 | |||||
|
Pegasys (Peginterferon alfa 2a) |
Immunomodulator |
Approved 2005 |
|||||||
| Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication | |||||||||
|
Epivir (Lamivudine) *Generics available |
Inhibits viral DNA polymerase | GlaxoSmithKline (GSK) | gsk.com | Approved 1998 | |||||
| Hepsera (Adefovir dipivoxil) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences, USA | gilead.com | Approved 2002 | |||||
|
Baraclude (Entecavir) *Generics available |
Inhibits viral DNA polymerase | Bristol-Myers Squibb, USA | bms.com | Approved 2005 | |||||
| Tyzeka (Telbivudine) *Generics available | Inhibits viral DNA polymerase | Novartis, USA | novartis.com | Approved 2006 | |||||
| Viread (Tenofovir) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences | gilead.com | Approved 2008 | |||||
| Vemlidy (TAF or tenofovir alafenamide) | Prodrug of Tenofovir | Gilead Sciences | gilead.com | Approved 2016 | |||||
|
Levovir (Cledvudine) |
Inhibits viral DNA polymerase | Bukwang, S. Korea | bukwang.co.kr | Approved 2006 in S. Korea | |||||
|
Direct Acting Antivirals: Targets the virus and interferes in the HBV replication process |
|||||||||
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
|||||||||
|
Imdurisan (AB-729) |
RNAi gene silencer |
Phase II | |||||||
|
BW-20507 |
RNAi gene silencer |
||||||||
|
DAP/TOM or daplusiran-tomligisiran (GSK7608) in combination with Bepirovirsen |
RNAi gene silencer |
||||||||
|
GSK 5637608 |
RNAi gene silencer |
gsk.com | Phase II | ||||||
|
HRS-5635 |
RNAi gene silencer |
Fujian Shengdi Pharma, PR China | hengrui.com/en | Phase II, PR China |
|||||
|
RBD1016 |
RNAi gene silencer |
Ribolia Life Sciences, PR China | ribolia.com/en | Phase II, Hong Kong and Sweden | |||||
|
HT-101 |
RNAi gene silencer |
hepathera.com | Phase II (outside USA) | ||||||
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
|||||||||
|
Hepalatide (with PEG-IFN) |
Entry inhibitor |
Phase II | |||||||
|
Capsid or Core Inhibitors: Interferes with the viral DNA protein shield |
|||||||||
|
ZM-H1505R |
Capsid inhibitor |
Phase II |
|||||||
|
Previfoscorvir sodium (ALG-000184) |
Capsid inhibitor |
aligos.com | Phase II | ||||||
|
EDP-514 |
Capsid inhibitor |
Enanta Pharma, USA (Seeks partner or in-licensing for development) |
Phase I |
||||||
|
ABI-4334 |
Capsid inhibitor |
Phase I | |||||||
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
|||||||||
|
REP 2139 |
sAg inhibitor |
Phase II |
|||||||
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
|||||||||
|
Bepirovirsen |
(ASO) HBV Antisense |
(ASO) GSK, USA |
US FDA Fast Track designation, April 2026 |
||||||
|
AHB-137 |
(ASO) HBV Antisense |
(ASO) AusperBio |
|||||||
|
ALG-170675 |
(ASO) Antisense |
Preclinical | |||||||
|
Gene Editing: Intended to destroy or repress HBV DNA |
|||||||||
|
TUNE-401 |
Epigenetic Silencing |
tunetx.com | Phase I/II | ||||||
| PBGENE-HBV | Gene Editing | precisionbiosciences.com | Phase I | ||||||
|
EPI-003 |
Epigenetic Silencing |
epigenictx.com |
Phase I, |
||||||
|
CRMA-1001 |
Epigenetic Silencing | nChromaBio, USA | nchromabio.com | Phase I | |||||
|
Immunologicals: Targets the human immune system to attack the HBV virus |
|||||||||
|
Therapeutic Vaccine Technology used to stimulate the immune system as a treatment |
|||||||||
|
VBI-2601 (BRII-179) |
Therapeutic vaccine |
VBI Vaccines with |
Phase II | ||||||
|
VTP-300 |
Therapeutic vaccine |
Phase II |
|||||||
|
CVI-HBV-002 |
Therapeutic vaccine |
AriBioLab (formerly Cha Vaccine Institute), S. Korea |
Phase II |
||||||
|
HBV Therapeutic Vaccine (GS2829/GS6779) |
Therapeutic vaccine |
gilead.com | Phase I | ||||||
|
ISA104 |
Therapeutic vaccine |
isa-pharma.com | Phase I | ||||||
|
VRON-0200 |
Therapeutic vaccine |
viriontx.com | Phase I | ||||||
| CLB-3000 |
Therapeutic vaccine |
Clear B Therapeutics, USA | clearbtherapeutics.com | Phase I | |||||
| TherVacB | Therapeutic vaccine | TherVacB, Germany | thervacb.eu | Phase I | |||||
| Launch-iT HBV (AVX70371) | Therapeutic vaccine | AstriVax, Belgium | astrivax.com | Phase I | |||||
| CARG-201 | Therapeutic vaccine | CaroGen, USA | carogencorp.com | Preclinical | |||||
|
AHB-837 |
(ASO) Therapeutic vaccine |
Preclinical |
|||||||
|
Compounds that activate the innate immune system |
|||||||||
|
Selgantolimod (GS9688) |
TLR-8 agonist |
Phase II |
|||||||
|
CB06 |
TLR-8 agonist |
core-biopharma.com | Phase I | ||||||
|
GSK 5251738 |
TLR-8 agonist |
gilead.com | Phase I | ||||||
|
Monoclonal Antibodies: Neutralize or bind the HBV proteins to reduce infection |
|||||||||
| Burfiralimab (IgG4) | Monoclonal antibody | ImmuneMed, South Korea | immunemed.co.kr/eng | Phase II | |||||
|
GIGA-2339 |
Polyclonal antibody | GigaGen, USA | gigagen.com | Phase I | |||||
|
HT-102 |
Monoclonal antibody | Hepa Thera, PR China | hepathera.com/eng | Preclinical | |||||
|
Checkpoint Inhibitors: Stimulate exhausted T-cell recognition of HBV-Infected cells |
|||||||||
|
ASC22 |
PDL1 inhibitor | Ascletis Pharma, PR China | ascletis.com | Phase II | |||||
|
AB-101 |
PDL1 inhibitor | Arbutus, USA | arbutusbio.com | Phase I | |||||
|
Other Immunologicals |
|||||||||
|
IMC-1109V |
T-cell Receptor | Immunocore, UK and USA | immunocore.com | Phase I | |||||
|
Additional HBV Drugs Under Investigation |
|||||||||
|
GSK 4388067A |
Targeted immunotherapy | GSK, USA | gsk.com | Phase II | |||||
|
APG-1387 |
Apoptosis inducer | Ascentage, PR China | ascentagepharma.com | Phase II | |||||
|
Elebsiran (VIR-2218), Tobevibart (VIR-3434) + PEG-IFN-a |
RNAi gene silencer and Monoclonal antibody | Vir Biotech, USA | vir.bio | Phase II - on hold for a partner | |||||
|
GSK 3965193 |
PAPD5/PAPD7 inhibitor |
GSK, USA | gsk.com | Phase I/II | |||||
|
DF-006 |
Small molecule | Drug Farm with Amoytop, PR China | drug-farm.com | Phase I | |||||
|
HBV |
Small molecule | Biotron Ltd, AU | Preclinical | ||||||
|
AB359 |
CD8 IL-2 immunotherapy | Asher Biotherapeutics, USA | Preclinical | ||||||
| MDL-001 | Direct-acting, broad spectrum antiviral | Model Medicines, USA | modelmedicines.com | Preclinical | |||||
|
Hepatitis Delta Virus (HDV) - A virus that co-infects people already infected with HBV |
|||||||||
|
Hepcludex (Bulevirtide) |
Entry inhibitor |
U.S. FDA Approved May 22, 2026, EU approved 2023 |
|||||||
|
Elebsiran (VIR-2218) and Tobevibart (VIR-3434) |
RNAi gene silencer + Monoclonal antibody | vir.bios | Phase III | ||||||
|
REP 2139 |
HBsAg inhibitor |
Phase II |
|||||||
|
Brelovitug (formerly BJT-778) |
Monoclonal antibody |
Phase II/III |
|||||||
|
RBD1016 |
RNAi gene silencer |
Phase II, Sweden | |||||||
|
Libevitug (HH-003) |
Monoclonal antibody |
Phase II, PR China | |||||||
|
ABI-6250 |
Entry inhibitor |
assemblybio.com | Preclinical | ||||||
|
MDL-001 |
Direct-acting, broad spectrum antiviral |
modelmedicines.com | Preclinical | ||||||
If you are a person with hepatitis B who is looking for clinical trial or other research opportunities, please visit our patient and provider opportunities page here.